Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan. The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.
Study Type
OBSERVATIONAL
Enrollment
306
CHRU de Brest
Brest, France
Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report
statistical analysis (%)
Time frame: 03/31/2020
All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3)
statistical analysis (%)
Time frame: 03/31/2020
Histology, differentiation status
qualitative description (text)
Time frame: 03/31/2020
mitotic index and proliferation idex of the tumor
statistical analysis (%)
Time frame: 03/31/2020
Response rate
statistical analysis (%)
Time frame: 03/31/2020
progression free survival
statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
Time frame: 03/31/2020
overall survival
statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
Time frame: 03/31/2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.